Leukemia

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial.

During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.

Treatment with Scemblix was shown to improve response rates in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic leukemia, among other diseases.

From “The Office” star opening up in a new interview to Charley Steiner revealing his multiple myeloma journey, here is this week’s cancer news.

Patients with relapsed or refractory CLL or SLL may benefit from receiving Brukinsa instead of Imbruvica, as Brukinsa demonstrated superior effectiveness.

More than 60% of patients with relapsed or refractory KMT2Ar acute leukemia responded to the menin inhibitor revumenib.

I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the bitterness of the pill, but in life too.

As a survivor of acute myeloid leukemia, some things are no longer going to be normal, but who wants to be normal?

From good news for a rock star to the deaths of stage and screen stars, here’s what’s happening in the cancer space this week.

CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies.

Before receiving treatment for acute myeloid leukemia, I made it a point to take advantage of all the resources that were available to me.

While spending weeks in the hospital for acute myeloid leukemia, I tried eight fun things to keep me busy.

The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

From Danielle Fishel and Rick Steves announcing their diagnosis to the “Emily in Paris” star discussing her cancer experience, here’s what’s happening in the oncology space this week.

As I visit the cancer center for chemotherapy to treat my CLL, I can’t help but take note of how different cancer may look in each person.

Researchers have identified genetic differences that can make leukemia relapse more or less likely among pediatric patients.

Researchers compared health-related quality of life among patients ages 60 and older with acute myeloid leukemia undergoing different chemotherapy regimens.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

During chemotherapy for my chronic lymphocytic leukemia, I try my best to appreciate the positive aspects of life, like flowers and friends.

After receiving cancer treatment and leaving the hospital, sometimes it feels like a safety net has been pulled away and loneliness sets in.

During my chemotherapy treatments for chronic lymphocytic leukemia, I had a supportive group of people surrounding me.

From “Top Chef’” Shirley Chung and comedian Christina Pazsitzky announcing their diagnoses to Erica Ash’s death from the disease, here is what’s happening in the oncology space this week.

I kept picking at these possibilities, grasping for reasons why cancer was happening to me rather than someone else.

It’s easy to fall into depression and anxiety during long hospitalizations for cancer, but creativity helped pull me out of those negative feelings.

When I was diagnosed with leukemia in 2004, it was before the days of social media. However, I still found an online support group that was very helpful.

When eating, walking and bathing became difficult after cancer, my daughter stepped in. I was proud of who she had become.

An FDA fast track designation was granted to DSP-5336, a novel treatment for patients with relapsed or refractory AML with KMT2A gene rearrangements.